About Tilt Biotherapeutics
TILT Biotherapeutics, founded in 2013, is a leading company globally working in the area of enabling tumor T-cell therapy with oncolytic viruses. The company’s patented technology is used to enhance tumor infiltrating lymphocyte (TIL), chimeric antigen receptor (CAR-T) and checkpoint inhibiting antibody therapy. TILT has secured almost 10M€ in funding and is now setting up phase I clinical trials, where its approach is further evaluated in cancer patients.
State of Ownership
Research Fellow, University of Western Australia
Business Development Executive, Nature Publishing Group, Springer Nature
Clinical trials Analyst at CBIO/NUDFAC-UFPE, CBIO/NUDFAC-UFPE
Sales Account Executive, Springer Nature